Summary
Regeneron Pharmaceuticals, Inc. reported robust financial performance for the fiscal year ended December 30, 2024, with revenues reaching $14.2 billion and net income of $4.4 billion, marking a significant increase from the prior year. The company's flagship products, EYLEA/EYLEA HD and Dupixent, continue to be key revenue drivers, with Dupixent in particular showing strong growth in collaboration revenue. Regeneron's extensive pipeline remains a focus, with numerous product candidates in various stages of clinical development across multiple therapeutic areas. The company is also actively managing its manufacturing and supply chain capabilities, investing in facility expansions and process validation to support future growth. Shareholder returns were bolstered by a new share repurchase program and the initiation of a quarterly dividend, indicating confidence in the company's financial health and future prospects.
Financial Highlights
48 data points| Revenue | $14.20B |
| R&D Expenses | $5.13B |
| SG&A Expenses | $2.95B |
| Operating Expenses | $10.21B |
| Operating Income | $3.99B |
| Net Income | $4.41B |
| EPS (Basic) | $40.90 |
| EPS (Diluted) | $38.34 |
| Shares Outstanding (Basic) | 107.90M |
| Shares Outstanding (Diluted) | 115.10M |
Key Highlights
- 1Revenues grew to $14.2 billion, and net income reached $4.4 billion for the fiscal year ended December 30, 2024.
- 2EYLEA HD and EYLEA U.S. net product sales increased by $82.8 million year-over-year, demonstrating continued demand.
- 3Sanofi collaboration revenue, primarily driven by Dupixent, increased to $4.53 billion, reflecting strong global performance.
- 4The company has a diverse and active clinical development pipeline with approximately 40 product candidates in development, including new indications for marketed products.
- 5Regeneron is expanding its manufacturing capacity and investing in new facilities, including a fill/finish facility in Rensselaer, New York.
- 6The company announced a new share repurchase program authorizing up to an additional $3.0 billion and initiated a quarterly cash dividend program.
- 7The company continues to leverage its proprietary VelociSuite® technology platforms and the Regeneron Genetics Center® for drug discovery and development.